Today Stories

- Similac® 360 Total Care® is the first and only infant formula with a blend of five different human milk oligosaccharides[1] (HMOs) across the three categories of HMOs in breast milk[2], the closest prebiotic blend to that of breast milk and previously only available to infants who are breastfed - Similac 360 Total Care with five HMOs is designed to support babies' developing immune system in the gut, where 70% of the immune system resides, promote digestive health and provide building blocks for babies' developing brains ABBOTT PARK, Ill., Nov. 16, 2021 -- Abbott (NYSE: ABT) today announced the launch of Similac 360 Total Care, the company's next generation of infant formula with HMOs, major prebiotics structurally identical to those found in human breast milk. Similac 360 Total Care is…

The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science. This is the first time that research scientists can conduct oncology research with Foundation Medicine’s comprehensive genomic profiling in their own laboratories to gain meaningful genomic insights and deepen their understanding of cancer biology. This kit is an important step forward in Roche and Foundation Medicine's vision of enabling personalised healthcare for more patients living with cancer by broadening access to CGP and making it essential in clinical decision making in the future. Basel, 25 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announc…

Ki-CONNECT collaboration seeks to offer clinical trial benefits to patients and the pharmaceutical industry BOSTON and Durham, N.C. Oct. 20, 2021 — Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, and Kyoto University Hospital today announced a strategic alliance aimed at providing more opportunities for clinical research and producing efficient and productive ways of supporting clinical studies. As part of Parexel’s Alliance Site network — consisting of more than 500 sites and over 17,000 investigators across the globe accelerating access to and enrollment of patient populations for clinical trials — Kyoto University Hospital will share their therapeutic expertise and opportunities to…

52 physicians from across the U.S. selected for the inaugural cohort of the five-year, $100 million initiative Initiative is part of the BMS Foundation commitment to health equity and diversity and inclusion made last year Applications are also now open for second cohort to begin in October 2022 PRINCETON, N.J.-- The Bristol Myers Squibb Foundation (BMSF), together with its partners, National Medical Fellowships (NMF) and the American Association for Cancer Research (AACR), today announced the first group of 52 physicians selected for its Diversity in Clinical Trials Career Development Program (BMSF DCTCDP). The 52 early-stage investigators are the first of 250 community-oriented clinical trialists who will be trained through the program by 2027. The 52 physicians selected by an indepe…

Boehringer Ingelheim has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology   Partners aim to expedite the development of the novel, inhaled cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy BI 3720931 as a long-lasting therapeutic option for patients with cystic fibrosis (CF)   Ingelheim, Germany, 19 October 2021 – Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium (GTC, consisting of researchers from Imperial College London and the Universities of Oxford and Edinburgh) and Oxford Biomedica (OXB), announced today that Boehringer Ingelheim has…

Rapid test results and certification designed to simplify international arrival Facial recognition and artificial intelligence features increase security and test result confidence Randox, the UK’s largest diagnostics company, today announces that it is launching the Randox CertiFly App, a mobile application designed to securely process and certify results for both pre departure and Day 2 lateral flow tests - the latter a requirement for vaccinated international arrivals in the UK from 24th October. The app, which applies ID verification technology, is designed to simplify foreign travel and facilitate the efficient transfer of secure and verified information through three simple steps: Step 1 – Download the Randox CertiFly App and scan your passport to register Step 2 – Collect your sa…

Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment. Collaboration with PathAI expands pathologist access to innovative AI-powered technology to support companion diagnostic and drug development programs. Builds on Roche’s Digital Pathology Open Environment, expanding the company’s commitment to improving patient outcomes and advancing personalised healthcare through innovation Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology. Under the development and distribution agreement, the companies will jointly develop an e…

Exhibitor Innovation Awards Routes of Administration - EVEON - Intuity® Spray Connected Devices & Wearables – Nemera - Symbioze Primary Packaging – ARaymondlife - OR2Pack Highly Commended – Heinlein - Flipdropper Excellence in Packaging Sustainability – Hoffman Neopac - Polyfoil® Mono-Material Barrier Tube   Health Product Awards Eco-Design UCB Pharma - CIMZIA 2x200mg Syringe Maintenance Kit Patient-Centric Design - Abbott Healthcare Ltd - AcuDose® Animal Health – Boehringer Ingelheim Vetmedica - Aservo® EquiHaler®   Paris, 13th-14th October 2021: Pharmapack Europe (#PharmapackEU) announce the winners of the 2021 Pharmapack Awards and, due to the exceptional quality of this year’s entries, seven winners have been chosen across both the ‘Exhibitor Innovation’ and ‘Health Product’ awards…

Inaugural ’Accelerate’ program designed and delivered by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs The University of Medicine Excellence will help Boehringer Ingelheim to accelerate progress in turning patient-focused innovation into life-changing treatments Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs Investment of 3.4 million USD until end of next year Ingelheim, October 12, 2021 – Boehringer Ingelheim today announced the launch of its University of Medicine Excellence (UME). In an unequivocal demonstration of commitment to people development and investm…

New UK-listed Consumer Healthcare company to build new global campus and innovation centre in Weybridge, UK GSK unveils longer-term plan to move to new UK headquarters GSK today announced proposals for a major new UK-based headquarters and global campus for the new Consumer Healthcare company following separation in 2022, and its long-term plan for the future headquarters of GSK. New Consumer Healthcare company headquarters to be based in Weybridge, UKThe proposals announced today form part of GSK’s ongoing work to prepare for the separation of the Group into two leading UK-based companies next year – new GSK, a global pharmaceuticals and vaccines company with an R&D approach focused on the science of the immune system, human genetics and advanced technologies, and a world leading Co…

Berkshire, UK. 11th October 2021. PharmiWeb.jobs, Europe's largest dedicated Life Science Job Board, has today launched a new US-focused version of their site. www.PharmiWeb.jobs/US/ The new site will help support both job seekers and recruiters in the Life Science sector right across North America. Since 1999, PharmiWeb has been the leading Job Board in the European Life Science industry, and their dedicated team has decades of experience helping recruiters find the best candidates, and job-seekers find the best jobs. Developed in partnership with Madgex, providers of the most sophisticated job board technology on the market, the new site brings Life Science jobs from across the US onto a dedicated new platform that offers the latest job-matching and searching functions. For recruiters, t…

Initiative to support a new generation of leaders in mRNA therapeutics and vaccine research CAMBRIDGE, Mass.--Oct. 6, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the launch of the Moderna Fellowship Program. The goal of the program is to support the next generation of scientists and healthcare professionals as they innovate in the field of mRNA research towards improving patient care and population health. Prospective fellows may be clinicians and scientists who are interested in advancing mRNA research and innovation and the program underpins Moderna’s commitment to supporting independent research. The fellowship program will select approximately 50 global fellows in the first year with a focus on…

Historic RTS,S/AS01 recommendation can reinvigorate the fight against malaria 6 October 2021 - News release - Geneva The World Health Organization (WHO) is recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission. The recommendation is based on results from an ongoing pilot programme in Ghana, Kenya and Malawi that has reached more than 800 000 children since 2019. “This is a historic moment. The long-awaited malaria vaccine for children is a breakthrough for science, child health and malaria control,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “Using this vaccine on top of existing  tools to prevent malaria could save tens of thousands of y…

CARLSBAD, Calif., Oct. 5, 2021 -- Since the emergence of SARS-CoV-2, public health laboratories and researchers have been developing surveillance methods using wastewater to control the spread of COVID-19. The effort has helped identify asymptomatic carriers on college campuses to monitor regional spread among communities and capture emerging mutations ahead of potential future outbreaks. To support these efforts, Thermo Fisher Scientific today introduced the MagMAX Wastewater Ultra Nucleic Acid Isolation Kit. Unlike other testing methods, which require nasal swabs or saliva samples, wastewater testing can assess infection rates among a general population up to two weeks earlier than individual or pooled testing. The MagMAX Wastewater Ultra Nucleic Acid Isolation Kit offers a flexible, eas…

- Cardio-renal-metabolic conditions are the leading cause of death worldwide, accounting for up to 20 million deaths in the U.S. annually RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 4, 2021 -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the launch of CRMSynced™, an educational initiative that uses gamification to encourage healthcare professionals (HCPs) to prioritize a holistic approach to care for cardio-renal-metabolic (C-R-M) conditions. Accounting for up to 20 million deaths in the U.S. annually, C-R-M conditions, including diabetes, heart disease and chronic kidney disease, are the leading causes of death worldwide. "Recent innovations in treatments and guidelines for those with C-R-M conditions have put a new level of responsibility on all members of the…

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has announced it has made a regulatory submission to the U.S. Food and Drug Administration (FDA) for approval of  a new dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine and, to extend its current approval for Triumeq (abacavir/ dolutegravir/ lamivudine) to lower the minimum weight at which a child can be prescribed this medicine, from 40kg and above to 14kg and above. If approved, this approval will result in further treatment options for younger children living with HIV. Paediatric HIV remains a global issue, with children disproportionately affected by the HIV epidemic. Latest statistics show there are 1.7 mi…

Acquisition Complements and Strengthens Merck’s Cardiovascular Pipeline Sotatercept is a Potentially First-In-Class Therapy in Phase 3 Development for the Treatment of Pulmonary Arterial Hypertension REBLOZYL ® (luspatercept-aamt) is a First-In-Class Erythroid Maturation Recombinant Fusion Protein Approved for the Treatment of Anemia in Certain Rare Blood Disorders Merck to Host Investor Call at 8 a.m. ET Today KENILWORTH, N.J. & CAMBRIDGE, Mass. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. (Nasdaq: XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approxima…

Breast Cancer Survivor, U.S. Olympian & High Jump American Record Holder Chaunté Lowe joins Komen, Lilly in taking action to improve breast cancer health equity Partnership to expand support services for Black women in the Midwest and across the U.S. to help close the 40% mortality gap in breast cancer INDIANAPOLIS and DALLAS, Sept. 29, 2021 -- Today, Eli Lilly and Company (NYSE: LLY) and Susan G. Komen®, the world's leading breast cancer organization, launched a new multiyear program to address breast cancer health disparities experienced by Black women in the U.S. Through the partnership, Lilly and Komen will expand existing resources that provide direct support to Black women facing breast cancer to meet their psychosocial needs, provide guidance to credible health information, a…

AstraZeneca will advance and accelerate ongoing Phase III clinical development of CAEL-101, a potential first-in-class medicine for AL amyloidosis AstraZeneca’s Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody (mAb) for the treatment of light chain (AL) amyloidosis. AL amyloidosis is a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys, causing significant organ damage and failure that may ultimately be fatal.1,2 Approximately 20,000 people across the US, France, Germany, Italy, Spain and the UK live with AL amyloidosis classified as Mayo stage IIIa or IIIb disease.3 CAEL-101 is currently being evalu…

Influenza results in approximately 5 million cases of severe illness and 290,000 to up to 650,000 deaths worldwide every year,1 with current seasonal vaccines preventing 40% to 60% of the disease in the best-matched seasons 2 mRNA-based vaccine design requires only the genetic sequences of the viruses, enabling more flexible, rapid manufacturing and the potential opportunity to improve upon the efficacy of current flu vaccines NEW YORK -- Pfizer Inc. (NYSE: PFE) announced today that the first participants have been dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of a single dose quadrivalent mRNA vaccine against influenza in healthy adults. Pfizer’s mRNA influenza vaccine program is the first in a planned wave of programs leveraging mRNA technol…